嵌合抗原受体修饰巨噬细胞改善临床前模型中的肝纤维化
本研究以靶向uPAR的嵌合抗原受体巨噬细胞(CAR-Ms)治疗小鼠肝纤维化模型。CAR-Ms可显著减轻肝纤维化并恢复肝功能,其机制包括调节肝脏免疫微环境、招募并修饰内源性免疫细胞,以及向T细胞呈递抗原诱导特异性抗纤维化T细胞反应。结论提示CAR-Ms可能成为肝纤维化的细胞治疗选择。
要点
- 靶向uPAR的CAR-Ms在多种小鼠肝纤维化模型中显著减轻纤维化并恢复肝功能。
- CAR-Ms通过调节肝脏免疫微环境、招募并修饰内源性免疫细胞驱动纤维化消退。
- CAR-Ms可招募T细胞、呈递抗原并诱导特异性抗纤维化T细胞反应。
核心结论
- CAR-Ms靶向uPAR可减轻小鼠肝纤维化与肝硬化,为肝纤维化提供潜在细胞治疗平台。
研究设计与样本
- 研究在多种小鼠肝纤维化模型中评估CAR-Ms的安全性与疗效,包括四氯化碳处理、5-二乙氧基羰基-1,4-二氢可力丁饮食及高脂/胆固醇/果糖饮食模型。
- uPAR表达在纤维化/肝硬化患者及小鼠肝纤维化模型中进行了研究。
主要发现
- 过继转移CAR-Ms可显著减轻小鼠肝纤维化并恢复功能。
- CAR-Ms调节肝脏免疫微环境,招募并修饰内源性免疫细胞以驱动纤维化消退。
- CAR-Ms能招募T细胞、向其呈递抗原并诱导特异性抗纤维化T细胞反应,减少成纤维细胞和肝纤维化。
临床怎么用
- 临床前证据提示CAR-Ms可能作为肝纤维化的细胞治疗方向,尚需进一步临床转化研究。
局限性
- 证据限于临床前小鼠模型,尚未在患者中验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Treatments directly targeting fibrosis remain limited. Given the unique intrinsic features of macrophages and their capacity to engraft in the liver, we genetically engineered bone marrow-derived macrophages with a chimeric antigen receptor (CAR) to direct their phagocytic activity against hepatic stellate cells (HSCs) in multiple mouse models. This study aimed to demonstrate the therapeutic efficacy of CAR macrophages (CAR-Ms) in mouse models of fibrosis and cirrhosis and to elucidate the underlying mechanisms. METHODS: uPAR expression was studied in patients with fibrosis/cirrhosis and in murine models of liver fibrosis, including mice treated with carbon tetrachloride, a 5-diethoxycarbonyl-1, 4-dihydrocollidine diet, or a high-fat/cholesterol/fructose diet. The safety and efficacy of CAR-Ms were evaluated in vitro and in vivo. RESULTS: Adoptive transfer of CAR-Ms resulted in a significant reduction in liver fibrosis and the restoration of function in murine models of liver fibrosis. CAR-Ms modulated the hepatic immune microenvironment to recruit and modify the activation of endogenous immune cells to drive fibrosis regression. These CAR-Ms were able to recruit and present antigens to T cells and mount specific antifibrotic T-cell responses to reduce fibroblasts and liver fibrosis in mice. CONCLUSION: Collectively, our findings demonstrate the potential of using macrophages as a platform for CAR technology to provide an effective treatment option for liver fibrosis. CAR-Ms might be developed for treatment of patients with liver fibrosis. IMPACT AND IMPLICATIONS: Liver fibrosis is an incurable condition that afflicts millions of people globally. Despite the clear clinical need, therapies for liver fibrosis are limited. Our findings provide the first preclinical evidence that chimeric antigen receptor (CAR)-macrophages (CAR-Ms) targeting uPAR can attenuate liver fibrosis and cirrhosis. We show that macrophages expressing this uPAR CAR exert a direct antifibrotic effect and elicit a specific T-cell response that augments the immune response against liver fibrosis. These findings demonstrate the potential of using CAR-Ms as an effective cell-based therapy for the treatment of liver fibrosis.
引用
- Dai H, Zhu C, Huai Q, et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. J Hepatol. 2024. PMID: 38340812. doi:10.1016/j.jhep.2024.01.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。